| Ytd | -19.06% | |
| 1y | 14.05% |
| Open | 629.48 | Prev Close | 623.54 | Low | 623.89 | High | 632.85 | Mkt Cap | 65.50B |
| Vol | 987.29K | Avg Vol | 991.68K | EPS | 40.98 | P/E | 15.24 | Forward P/E | 11.62 |
| Beta | 0.24 | Short Ratio | 2.72 | Inst. Own | 92.23% | Dividend | 3.76 | Div Yield | 0.60 |
| Ex Div Date | 05-20 | Earning | 07-30 | 50-d Avg | 659.41 | 200-d Avg | 699.49 | 1yr Est | 833.31 |
REGN News
It might pull it off, provided several things fall right in place.
FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after recei
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven compa
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin
Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.co
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill
The FDA will review the New Drug Application (NDA) under Priority Review with a target action date i
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that new clinical data and research fr
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu
Normalization of free light chains occurred by day 15 across all doses100% of patients achieved a he
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Bu
BMO Capital analyst Evan David Seigerman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a
Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and t
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a
JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweigh
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overwei
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-W
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Secto
Citigroup analyst Geoff Meacham downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Buy to Ne
Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper
Wall Street analysts changed ratings on top stocks. Check out the complete list on Benzinga's an
Leerink Partners analyst Andrew Berens downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Ou
Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the st
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Mon
REGN: -11% | Regeneron Fianlimab Combination Fails To Reach Statistical Significance In First-Line U
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a strategic research collaboration wit
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free
Liveramp Holdings Inc (NYSE: RAMP) rose in pre-market trading after being acquired by Publicis for $
The trial did not reach statistical significance for the primary endpoint of improvement in progress
Citigroup cut RCL's price target, TD Cowen raised COHU's price target, JP Morgan cut SYK'
Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Secto
Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q1 earnings and a $3B share buyback. Analys
Barclays analyst Eliana Merle maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-W
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on man
Crude oil rocketed nearly 6% on a stalled US-Iran standoff while stocks drifted lower ahead of the F
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.47 per share which beat th
Regeneron agrees to cut U.S. drug prices, offers free gene therapy, and expands access under a deal
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and
https://www.bloomberg.com/news/articles/2026-04-23/regeneron-s-gene-therapy-for-deaf-children-wins-f